NCT04755985View on ClinicalTrials.gov

A Study to Compare PK, PD and Safety of the AD-213-B and AD-2132

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 21, 2021

Primary Completion Date

May 13, 2021

Study Completion Date

July 23, 2021

Conditions
Gastroesophagus Reflux Disease
Interventions
DRUG

AD-213-B

1 tablet administered before the breakfast during 5 days

DRUG

AD-2132

1 tablet administered before the breakfast during 5 days

Trial Locations (1)

Unknown

Young-Ran Yoon, Daegu

All Listed Sponsors
lead

Addpharma Inc.

INDUSTRY

NCT04755985 - A Study to Compare PK, PD and Safety of the AD-213-B and AD-2132 | Biotech Hunter | Biotech Hunter